Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Immunopathogenesis and therapy of cutaneous T cell lymphoma Kim EJ; Hess S; Richardson SK; Newton S; Showe LC; Benoit BM; Ubriani R; Vittorio CC; Junkins-Hopkins JM; Wysocka M; Rook AHJ Clin Invest 2005[Apr]; 115 (4): 798-812Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4(+)/CLA(+)/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.|*Immunotherapy/methods[MESH]|*Lymphoma, T-Cell, Cutaneous/etiology/immunology/pathology/therapy[MESH]|*Skin Neoplasms/etiology/immunology/pathology/therapy[MESH]|Antigens, CD/immunology[MESH]|Humans[MESH]|Neoplasm Staging[MESH]|Skin/cytology/pathology[MESH]|Survival Rate[MESH]|T-Lymphocyte Subsets/immunology[MESH]|T-Lymphocytes/immunology[MESH] |
